Comparing between Hydroxyurea and Non-Hydroxyurea Anti-inflammatory Cytokines in Sickle Cell Anemia Saudi Patients

被引:0
|
作者
Tarbiah, Nesrin, I [1 ]
Alamri, Reema S. [1 ]
Alkhattabi, Nuha A. [1 ]
Alhemadi, Maryam M. [1 ]
Almutairi, Huda S. [1 ]
Alzahri, Reem Y. [2 ]
Hussain, Hend [3 ]
机构
[1] King Abdulaziz Univ, Dept Biochem, Jeddah, Saudi Arabia
[2] Jeddah Univ, Dept Biol, Jeddah, Saudi Arabia
[3] King Abdulaziz Univ, Dept Hematol, Jeddah, Saudi Arabia
关键词
Anti-inflammatory cytokines; Hydroxyurea; Inflammation; Sickle cell disease; DISEASE PATIENTS; IL-37;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Sickle Cell Anemia (SCA) is a hemolytic deficiency that is typified by strangely formed (sickles) red blood cells that are expelled from circulation at expanded rates, leading to anemia. It is caused by inheritance of hemoglobin (Hb) that has mutated, which compared to adult normal Hb, contains a single amino acid substitution, where at the sixth residue valine substitutes glutamic acid in the Hb tetramer in both of the two B chains. For SCA patients, chronic inflammatory conditions are linked to high levels of inflammation markers, including cytokines and adhesion molecules. Cytokines are a group of small proteins that are essential in cell signaling. The immuno regulatory molecules known as anti-inflammatory cytokines control the response of pro inflammatory and have gained attention recently as anti-inflammatory mediator in SCA patients. The most interesting anti-inflammatory cytokines are IL-10, IL-4, IL-27, and IL-37. This a case-control study aimed to measure the concentrations of the anti-inflammatory cytokines in 3 groups, SCA patients without the use of any medication, SCA patients under Hydroxy Urea therapy (SCAHU), and healthy people (male and female) in the general Saudi population, using a total of 78 chosen subjects. Using ELISA kits, cytokine levels were measured in the plasma of the patients. The results of the study indicated that anti-inflammatory cytokines were elevated in SCA and SCAHU patients when compared to the control (P=0.001), and there were no significant differences between SCA and SCAHU patients. The anti-inflammatory cytokines, including IL-27 and IL-37, that were detected for the first time in SCA patients in KSA in this research, have a role in keeping patients in a steady-state and reducing inflammation, therefore more research to understand the roles of these cytokines in SCA pathology of is essential to allow the development of effective therapies to treat this disease.
引用
收藏
页码:39 / 44
页数:6
相关论文
共 50 条
  • [31] Cerebral Metabolic Stress Is Lower in Patients with Sickle Cell Anemia on Hydroxyurea Therapy
    Fields, Melanie E.
    Guilliams, Kristin P.
    Binkley, Michael M.
    Ragan, Dustin K.
    Fellah, Slim
    Eldeniz, Cihat
    Chen, Yasheng
    Hulbert, Monica L.
    McKinstry, Robert C.
    Shimony, Joshua S.
    Vo, Katie D.
    An, Hongyu
    Ford, Andria L.
    Lee, Jin-Moo
    BLOOD, 2017, 130
  • [32] How I use hydroxyurea to treat young patients with sickle cell anemia
    Ware, Russell E.
    BLOOD, 2010, 115 (26) : 5300 - 5311
  • [33] Evaluation of the concentration of malondialdehyde and nitrite in patients with sickle cell anemia treated or not with hydroxyurea
    Dias Elias, Darcielle Bruna
    de Freitas, Rivelilson Mendes
    Goncalves, Romelia Pinheiro
    Ferreira Magalhaes, Hemerson Yuri
    de Sousa, Jacqueline Holanda
    Meira Magalhaes, Silvia Maria
    EINSTEIN-SAO PAULO, 2010, 8 (04): : 414 - 418
  • [34] Longitudinal Analysis of Hydroxyurea and Fetal Hemoglobin in Adult Patients with Sickle Cell Anemia
    Pelcovits, Aryeh
    Riotto, Giancarlo
    Cherenzia, Katie
    McGann, Patrick T.
    Reagan, John L.
    BLOOD, 2021, 138
  • [35] Effect of hydroxyurea on the deformability of the red blood cell membrane in patients with sickle cell anemia
    Athanassiou, G.
    Moutzouri, A.
    Kourakli, A.
    Zoumbos, N.
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2006, 35 (1-2) : 291 - 295
  • [36] Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia
    Gohal, Gassem A.
    Gosadi, Ibrahim
    Iqbal, Basheer Ahmed Cittana
    Ghazwani, Yahya H.
    Daghriri, Amal M.
    Shugairi, Ahmad A.
    Daghriri, Khaled A.
    Zurayyir, Atyaf J.
    Nemri, Abdulrhman A.
    Abdulhaq, Monera
    PATIENT PREFERENCE AND ADHERENCE, 2022, 16 : 3059 - 3067
  • [37] Hydroxyurea usage awareness among patients with sickle-cell disease in Saudi Arabia
    Alsalman, Mortadah
    Alkhalifa, Hussain
    Alkhalifa, Ali
    Alsubie, Mustafa
    AlMurayhil, Nora
    Althafar, Abdulaziz
    Albarqi, Mohammed
    Alnaim, Abdulrahman
    Khan, Abdul Sattar
    HEALTH SCIENCE REPORTS, 2021, 4 (04)
  • [38] Genotoxicity of Hydroxyurea in Mice Measured at Doses Relevant to Pediatric Sickle Cell Anemia Patients
    Hobbs, C. A.
    Recio, L.
    Shepard, K.
    Green, A.
    Winters, J.
    Baldetti, C.
    Streicker, M.
    Witt, K. L.
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2010, 51 (07) : 727 - 727
  • [39] Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity
    Maia Filho, Pedro Aurio
    Pereira, Jamilly Florencio
    de Almeida Filho, Tarcisio Paulo
    Cavalcanti, Bruno Coelho
    de Sousa, Juliana Cordeiro
    Goncalves Lemes, Romelia Pinheiro
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2019, 60 (03) : 302 - 304
  • [40] Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia
    Ghasemi, A.
    Keikhaei, B.
    Ghodsi, R.
    IRANIAN JOURNAL OF PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2014, 4 (03) : 114 - 117